Drawing for ZENLIST

USPTO serial 85183671

ZENLIST

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
Examiner
PINO, BRIAN
Law office
TMO LAW OFFICE 114 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ZENLIST?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Robert E. Lee, Jr.

ROBERT E. LEE, JR. ELI LILLY AND COMPANYLILLY CORPORATE CENTERINDIANAPOLIS, IN 46285-0001UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, anxiety, bone and skeletal diseases and disorders, blood disorders, cancer, cardiovascular diseases, cholesterol disorders, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders; antipsychotics; antidepressants; pharmaceutical preparations for use in the treatment of anxiety spectrum disorders, atherosclerosis and Alzheimer's; pharmaceutical preparations for use in the treatment of diabetes; pharmaceutical preparations for use in the treatment of rheumatoid arthritis; pharmaceutical preparations for use in the treatment of Crohn's disease, systemic lupus erythematosus, and ankylosing spondylitis disease; pharmaceutical preparations for use in the treatment of psoriasis and psoriatic arthritis; pharmaceutical preparations for use in the treatment of autoimmune disorders; Veterinary preparations for companion animals in the treatment of weight loss, obesity, urine spraying, chronic pain, gastrointestinal disorders, neurodegenerative disorders, parasitic infestations, neurological disorders, anxiety, hypertension, dermatitis, cancer, anemia associated with chronic renal failure, fleas, pain associated with orthopedic and soft tissue surgery, chronic kidney disease, and emesis; preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; veterinary preparations for the treatment, control and symptomatic relief of infectious and metabolic diseases of livestock; dietary food supplements for animals; antibacterial pharmaceuticals; production enhancement for livestock, namely, medicated feed and medicated water additives; medicated feed additives and medicated water additives for animals; diagnostic agents, preparations, and substances to identify pathogens or residues of biological interest for veterinary useACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 19, 2011MAB1ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT
Sep 19, 2011ABN1ABANDONMENT - EXPRESS MAILED
Sep 16, 2011EXARTEAS EXPRESS ABANDONMENT RECEIVED
Sep 9, 2011ALIEASSIGNED TO LIE
Mar 8, 2011GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 8, 2011GNSLLETTER OF SUSPENSION E-MAILED
Mar 8, 2011CNSLSUSPENSION LETTER WRITTEN
Mar 1, 2011DOCKASSIGNED TO EXAMINER
Nov 30, 2010MPMKNOTICE OF PSEUDO MARK MAILED
Nov 29, 2010NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 26, 2010NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance